Gatifloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
miglitol
α-Glucosidase inhibitor · Antidiabetic agent
α-Glucosidase inhibitorAntidiabetic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- GatifloxacinSevereDatabaseDDInter
Mechanism
Miglitol reduces the intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α-glucosidase in the intestinal brush border. This slows down carbohydrate digestion and absorption, reducing postprandial glucose excursions.
Indications
Adjunct to diet and exercise in type 2 diabetesUsed in combination with other oral antidiabetic agents or insulintype 2 diabetes mellitus
Dosing
- Adult
- 25–100 mg three times daily (at the beginning of each meal)
Pharmacokinetics
Bioavailability
Substantial, but variable absorption
Metabolism
Not specified
Excretion
Almost entirely by the kidney
Side effects
Common
MalabsorptionFlatulenceDiarrheaAbdominal bloating
Serious
- Cutaneous hypersensitivity (rare)
Drug interactions
11 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Gestational diabetes mellitus
FOGSI · Obstetrics & Gynaecology · 2023
Heart failure in diabetes
RSSDI · Cardiology · 2023
Fluid and electrolyte management in diabetes
RSSDI · Endocrinology · 2025
Diabetes management during Ramadan
ADA · Endocrinology · 2025
Glucose monitoring in diabetes
RSSDI · Endocrinology · 2024
Ask House about miglitol
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e·Updated: 2026-05-10